Inhibrx Biosciences, Inc. Common Stock (INBX) Stock
NASDAQ · INBX
109.35
Fundamentals
Market cap
$1.61B
Price / Earnings ratio
-11.2x
Price / Sales ratio
1094.8x
Price / Book ratio
-29.1x
Return on assets
-0.7%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
SectorHealthcare
IndustryBiotechnology
Employees109
CEOMr. Mark Paul Lappe
IPO DateMay 29, 2024
HeadquartersLa Jolla, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Paul Lappe | Founder, CEO & Chairman | 1967 |
| Mr. David J. Matly M.B.A. | President | 1986 |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | 1980 |
| Ms. Bonne Adams M.B.A. | Vice President of Operations | 1977 |
| Ms. Kate Burke CPA, M.B.A. | Vice President of Accounting | — |
| Dr. Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer | 1968 |
| Dr. Carlos Bais Ph.D. | EVP & Chief Scientific Officer | — |
| Ms. Leah Pollema J.D. | VP, General Counsel & Corporate Secretary | — |
| Dr. Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | — |
Fundamentals
Valuation
Market cap$1.61B
Price-to-sales ratio1,094.85
Price-to-book value-29.10
Price-earnings ratio-11.20
Return on Equity-564.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-8.88
Income Statement
Average volume367,646
EBITDA$-112.97M
1 year high (52w)$155.29
1 year low (52w)$26.20
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



